Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
https://www.fool.com/investing/2024/07/09/can-eli-lilly-surpass-1000-this-year/?source=iedfolrf0000001
Jul 09, 2024 - This pharma company is posting double-digit revenue growth.
0
If You Invested $1000 in Eli Lilly a Decade Ago, This is How Much It'd Be Worth Now
https://www.zacks.com/stock/news/2297887/if-you-invested-1000-in-eli-lilly-a-decade-ago-this-is-how-much-it-d-be-worth-now?cid=CS-ZC-FT-tale_of_the_tape|investing_$1000-2297887
Jul 08, 2024 - Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
0
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
https://www.zacks.com/stock/news/2297256/pharma-stock-roundup-fda-nod-to-lly-s-kisunla-sny-s-dupixent-gets-eu-nod-for-copd?cid=CS-ZC-FT-analyst_blog|stock_roundup-2297256
Jul 05, 2024 - Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.
0
Missed Out on Eli Lilly? This Much Smaller Biotech Has 2 Promising Weight Loss Assets in its Portfolio
https://www.fool.com/investing/2024/07/05/missed-out-on-eli-lilly-this-much-smaller-biotech/?source=iedfolrf0000001
Jul 05, 2024 - Could Zealand Pharma be a better option for growth-oriented investors?
0
NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
https://www.zacks.com/stock/news/2296877/nvo-lly-slip-after-study-links-obesity-drug-use-to-vision-loss?cid=CS-ZC-FT-analyst_blog|industry_focus-2296877
Jul 04, 2024 - A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
0
Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation
https://www.fool.com/investing/2024/07/04/mounjaro-and-zepbound-are-great-but-this-is-the-re/?source=iedfolrf0000001
Jul 04, 2024 - Investors shouldn't assume that all of the company's future growth is already priced into the stock's valuation.
0
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
https://www.zacks.com/stock/news/2296481/eli-lilly-lly-gets-fda-nod-for-alzheimer-s-drug-donanemab?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2296481
Jul 03, 2024 - Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.
0
How Great Is It to Have Customers That Absolutely Love You and Plan to Never Leave You?
https://www.fool.com/investing/2024/07/02/customers-for-life/?source=iedfolrf0000001
Jul 02, 2024 - We also talk about weight loss drugs and sleep apnea, and other stock market news.
0
Want Decades of Passive Income? 2 Top Dividend Stocks to Buy Now and Hold Forever.
https://www.fool.com/investing/2024/07/01/passive-income-top-dividend-stocks-to-buy/?source=iedfolrf0000001
Jul 01, 2024 - These stalwart companies could help you safely grow your wealth.
0
This Is Massive News for Eli Lilly Investors
https://www.fool.com/investing/2024/06/29/this-is-massive-news-for-eli-lilly-investors/?source=iedfolrf0000001
Jun 29, 2024 - A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate.
0